Compare RCAT & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCAT | DBVT |
|---|---|---|
| Founded | 2002 | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Wholesale Distributors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 957.4M | 1.1B |
| IPO Year | 2017 | 2014 |
| Metric | RCAT | DBVT |
|---|---|---|
| Price | $15.56 | $20.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $16.33 | ★ $31.75 |
| AVG Volume (30 Days) | ★ 15.6M | 213.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,836,382.00 | $4,151,000.00 |
| Revenue This Year | $438.56 | $65.50 |
| Revenue Next Year | $265.21 | $47.02 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 79.95 | N/A |
| 52 Week Low | $4.60 | $3.91 |
| 52 Week High | $18.78 | $26.19 |
| Indicator | RCAT | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 59.50 | 45.16 |
| Support Level | $10.39 | $20.23 |
| Resistance Level | $17.83 | $25.00 |
| Average True Range (ATR) | 1.73 | 1.59 |
| MACD | 0.26 | -0.24 |
| Stochastic Oscillator | 59.71 | 34.74 |
Red Cat Holdings Inc is a drone technology company integrating robotic hardware and software for military, government, and commercial operations. Red Cat's suite of solutions includes the Arachnid family of ISR and precision strike drones, which includes the Black Widow, a small unmanned ISR system; and WEB (Warfighter Electronic Bridge) GCS, designed to command and control an entire drone family of systems for military operations. Its other offerings include Edge 130 Blue drone systems, Trichon, a fixed-wing VTOL for extended endurance and range, and FANG FPV drones optimized for military operations with precision strike capabilities.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.